Cargando…

Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies

Thrombotic microangiopathies (TMAs) are multiple disease entities with different etiopathogeneses, characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytosis, variable symptoms including fever, and multi-organ failure such as mild renal impairment and neurologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Zini, Gina, De Cristofaro, Raimondo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863018/
https://www.ncbi.nlm.nih.gov/pubmed/31337190
http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0165
_version_ 1783471681351712768
author Zini, Gina
De Cristofaro, Raimondo
author_facet Zini, Gina
De Cristofaro, Raimondo
author_sort Zini, Gina
collection PubMed
description Thrombotic microangiopathies (TMAs) are multiple disease entities with different etiopathogeneses, characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytosis, variable symptoms including fever, and multi-organ failure such as mild renal impairment and neurological deficits. The two paradigms of TMAs are represented on one hand by acquired thrombotic thrombocytopenic purpura (TTP) and on the other by hemolytic uremic syndrome (HUS). The differential diagnosis between these two paradigmatic forms of TMA is based on the presence of either frank renal failure in HUS or a severe deficiency (<10%) of the zinc-protease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) in TTP. ADAMTS13 is an enzyme involved in the proteolytic processing of von Willebrand factor (vWF), and its deficiency results in formation of high-molecular-weight vWF-rich microthrombi in the environment of the microvasculature. The presence of these ultra-large vWF multimers in the microcirculation can recruit platelets, promoting multi-organ ischemic lesions. The presence of ADAMTS13 activity at >10% could rule out the presence of a TTP form. However, it is often difficult to differentiate either a TTP or HUS clinical scenario presenting with typical symptoms of TMA. There are in fact several additional diagnoses that should be considered in patients with ADAMTS13 activity of >10%. Widespread inflammation with endothelial damage and adverse reactions to drugs play a central role in the pathogenesis of several forms of TMA, and in these cases, the differential diagnosis should be directed at the underlying disease. Hence, a correct etiologic diagnosis of TMA should involve a critical illness, cancer-associated TMA, drug-induced TMA, and hematopoietic transplant-associated TMA. A complete assessment of all the possible etiologies for TMA symptoms, including acquired or congenital TTP, will allow for a more accurate diagnosis and application of a more appropriate treatment.
format Online
Article
Text
id pubmed-6863018
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-68630182019-12-04 Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies Zini, Gina De Cristofaro, Raimondo Turk J Haematol Review Thrombotic microangiopathies (TMAs) are multiple disease entities with different etiopathogeneses, characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytosis, variable symptoms including fever, and multi-organ failure such as mild renal impairment and neurological deficits. The two paradigms of TMAs are represented on one hand by acquired thrombotic thrombocytopenic purpura (TTP) and on the other by hemolytic uremic syndrome (HUS). The differential diagnosis between these two paradigmatic forms of TMA is based on the presence of either frank renal failure in HUS or a severe deficiency (<10%) of the zinc-protease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) in TTP. ADAMTS13 is an enzyme involved in the proteolytic processing of von Willebrand factor (vWF), and its deficiency results in formation of high-molecular-weight vWF-rich microthrombi in the environment of the microvasculature. The presence of these ultra-large vWF multimers in the microcirculation can recruit platelets, promoting multi-organ ischemic lesions. The presence of ADAMTS13 activity at >10% could rule out the presence of a TTP form. However, it is often difficult to differentiate either a TTP or HUS clinical scenario presenting with typical symptoms of TMA. There are in fact several additional diagnoses that should be considered in patients with ADAMTS13 activity of >10%. Widespread inflammation with endothelial damage and adverse reactions to drugs play a central role in the pathogenesis of several forms of TMA, and in these cases, the differential diagnosis should be directed at the underlying disease. Hence, a correct etiologic diagnosis of TMA should involve a critical illness, cancer-associated TMA, drug-induced TMA, and hematopoietic transplant-associated TMA. A complete assessment of all the possible etiologies for TMA symptoms, including acquired or congenital TTP, will allow for a more accurate diagnosis and application of a more appropriate treatment. Galenos Publishing 2019-12 2019-11-18 /pmc/articles/PMC6863018/ /pubmed/31337190 http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0165 Text en © Copyright 2019 by Turkish Society of Hematology / Turkish Journal of Hematology, Published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Zini, Gina
De Cristofaro, Raimondo
Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies
title Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies
title_full Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies
title_fullStr Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies
title_full_unstemmed Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies
title_short Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies
title_sort diagnostic testing for differential diagnosis in thrombotic microangiopathies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863018/
https://www.ncbi.nlm.nih.gov/pubmed/31337190
http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0165
work_keys_str_mv AT zinigina diagnostictestingfordifferentialdiagnosisinthromboticmicroangiopathies
AT decristofaroraimondo diagnostictestingfordifferentialdiagnosisinthromboticmicroangiopathies